Search Results - immune+checkpoint+inhibitor

2 Results

Sort By:

Immunotherapy Combination Treatment Containing both TLR4 and TLR2/6 Agonists, a Checkpoint Inhibitor, and a STING agonist.

Abstract: Melanoma is an aggressive form of skin cancer that commonly becomes metastatic, spreading to nearby tissue or other parts of the body, including distant skin or subcutaneous sites such as the lungs, liver, brain, or bone. Metastatic melanoma is very drug resistant and difficult to treat, and therefore, the prognosis for these patients is poor....

Published: 5/22/2024 | Inventor(s): Md Alam, De Yang, Joost Oppenheim

Keywords(s): cGAMP, Combination Therapy, FSL-1, HMGN1, Immune Checkpoint Inhibitor, Immunotherapy, Melanin-Producing Melanoma, MELANOMA, Oppenheim, RESISTANT, STING Agonist, TLR, TLR2/6, TLR4, TLR4 Agonist, Toll-like receptor, TRL2/6 Agonist

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors

Abstract: Programed Death-Ligand 1 (PD-L1, also known as B7-H1 or CD274) is a cell surface protein that binds to Programmed Cell Death Protein 1 (PD-1, also known as CD279). An imbalance in PD-1/PD-L1 activity contributes to cancer immune escape. PD-1 is expressed on the surface of antigen-stimulated T cells. The interaction between PD-L1 and PD-1...

Published: 4/8/2024 | Inventor(s): Mitchell Ho, Glenn Merlino, Dan Li, Hejiao English, Chi-Ping Day

Keywords(s): adoptive cell therapy, Chimeric Antigen Receptor T Cells, HO, ICI, Immune Checkpoint Inhibitor, Immunotherapy, NANOBODY, PD-L1, phage display, Programed Death-Ligand, Single Domain Antibody

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology